GlassScriptPhysician profile
Robert Lee Lewis
NPI 1811097348
$72,578.34
in general payments reported to CMS, 2019-2025
33 companies · $1,137 in 2025
The $1,137 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157 · 2020: $304 · 2021: $13K · 2022: $52K · 2023: $4,895 · 2024: $1,759 · 2025: $1,137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,294 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,250 · Education: $247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,294.43 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,250.00 |
| Education | $246.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viz.Ai, INC. | $42,391.00 | 2022 | |
| Abbvie INC. | $25,944.54 | 2021-2025 | |
| Allergan, INC. | $867.94 | 2020-2021 | |
| Pfizer INC. | $625.32 | 2023-2025 | |
| Ucb, INC. | $491.26 | 2022-2025 | Briviact, Nayzilam, Rystiggo |
| Biohaven Pharmaceutical Holding Company LTD. | $346.09 | 2022 | |
| Amgen INC. | $280.81 | 2020-2022 | |
| Jazz Pharmaceuticals INC. | $275.11 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $224.54 | 2019-2024 | Ultomiris |
| Biogen, INC. | $131.94 | 2020-2022 | |
| Alnylam Pharmaceuticals INC. | $125.00 | 2021 | |
| Ani Pharmaceuticals, INC. | $124.46 | 2023 | Purified Cortrophin Gel |
| Emd Serono, INC. | $79.71 | 2022-2023 | Mavenclad |
| Vanda Pharmaceuticals INC. | $77.77 | 2024 | Ponvory |
| Medtronic, INC. | $76.19 | 2023 | Percept PC Brainsense |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $73.02 | 2019-2025 | |
| Akcea Therapeutics, INC. | $69.53 | 2020 | |
| Tanabe Pharma America, INC. | $63.33 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $38.36 | 2022-2023 | Ingrezza, Ongentys |
| Supernus Pharmaceuticals, INC. | $33.24 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $30.62 | 2023 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $23.31 | 2021 | |
| Greenwich Biosciences, INC. | $22.43 | 2019 | |
| Argenx US, INC. | $20.63 | 2025 | Vyvgart Hytrulo |
| Medtronic USA, INC. | $19.26 | 2019 | |
| Banner Life Sciences, LLC | $18.74 | 2022 | |
| Boston Scientific Corporation | $17.28 | 2019 | |
| Tg Therapeutics, INC. | $16.80 | 2025 | |
| Neurelis, INC. | $16.36 | 2020 | |
| Kyowa Kirin, INC. | $14.34 | 2019 | |
| Livanova USA, INC. | $14.29 | 2020 | |
| Acorda Therapeutics, INC | $12.96 | 2019 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.